
European Union (EU) antitrust regulators are set to engage with rivals of Telecom Italia (TIM) next week to deliberate over the proposed acquisition of the former phone monopoly’s domestic fixed-line network by U.S. investment firm KKR, as per two insider sources on Wednesday.
The EU Commission, approached for comment on the matter, refrained from providing any official statement.
TIM’s competitors were given until April 30 to respond to EU questionnaires, as relayed by sources to Reuters earlier. The European Union queried rivals about the potential anti-competitive implications of the deal, valued at up to 22 billion euros ($23.6 billion), which encompasses a master service agreement between TIM’s remaining service entity and the future wholesale network operator. The inquiry will assess whether this transaction could impede competition in the market.
Related: EU to Decide on KKR’s Telecom Italia Buyout by May 30
These regulatory apprehensions might precipitate an extensive investigation into the deal, exerting pressure on KKR to propose substantial remedies to alleviate concerns.
The sale forms part of a government-supported initiative aimed at reducing debt and revitalizing TIM. According to reports by Reuters, TIM intends to conclude the deal around the middle of the year, and any delay could complicate the company’s restructuring efforts.
Source: Reuters
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas